| pubmed-article:11868696 | pubmed:abstractText | Biochemical markers are of increasing importance in diagnostic strategies for ruling in and ruling out acute myocardial infarction (AMI), particularly when electrocardiographic (ECG) findings do not allow a diagnosis. Point-of-care testing (POCT) or "near-patient" testing allows for diagnostic assays to be performed at the site of patient care delivery. The biochemical markers that are commonly used by physicians to aid in the diagnosis of AMI are myoglobin, CK-MB, troponin I, and troponin T. Currently available POCT assays possess comparable diagnostic performance to laboratory-based cardiac marker assays. This provides an opportunity for POCT to evolve into the standard of care for evaluating the greater than 6 million American patients presenting with chest discomfort. Full acceptance of this relatively new technology will not be realized until users reach a comfort level where utilization of these devices is foolproof and they have faith in the results. | lld:pubmed |
